Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Genetic Variant Associated With Resistance To Chemotherapy Drug In Women With Breast Cancer
Researchers have found links between an individual"s genetics and their response to treatment with chemotherapy. The findings, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, show how a genetic variation, located in the SOD2 gene, may affect how a person responds to the chemotherapy drug cyclophosphamide. Cyclophosphamide is used in the treatment of breast and other cancers.

AARP Presses Lawmakers To Support Long Term Care
AARP Executive Vice President Nancy LeaMond released
News of the day
Embryo Movement Stimulates Joint Formation
A new study uncovers a molecular mechanism that explains why joints fail to develop in embryos with paralyzed limbs. The research, published by Cell Press in the May issue of the journal Developmental Cell, answers a longstanding question about the influence of muscle activity on developing joints and underscores the critical contribution of movement to regulation of a signaling pathway that is important during development and beyond.
Diagnostics

2009/044 NICE Issues Final Guidance On The Use Of Rituximab For First Line Chronic Lymphocytic Leukaemia

The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published guidance on the use of rituximab for the first line treatment of chronic lymphocytic leukaemia. The guidance recommends that rituximab should be considered asa possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide. Rituximab should only be used in combination with fludarabine and cyclophosphamide. Rituximab is not recommended in combination with any other chemotherapy agents as a first treatment for chronic lymphocytic leukaemia. Chronic lymphocytic leukaemia is the most common form of adult leukaemia and is a cancer of the white blood cells (lymphocytes). The cancerous lymphocytes multiply in an uncontrolled way and stop normal white blood cells, red blood cells and platelets (blood fragments that have a role in the clotting of blood) from working properly. Dr Carole Longson, NICE Health Technology Evaluation Centre Director said: "After looking at all of the available evidence the independent Appraisal Committee concluded that rituximab, when used as a first line treatment for people with with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide, represented an effective use of NHS res. This important guidance increases the treatment options available to people with this condition, wherever they live in England and Wales." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009